MedPath

DEKK-TEC, INC.

DEKK-TEC, INC. logo
πŸ‡ΊπŸ‡ΈUnited States
Ownership
Private
Established
1983-01-01
Employees
1
Market Cap
-
Website
http://www.dekk-tec.com

Clinical Trials

7

Active:0
Completed:6

Trial Phases

2 Phases

Phase 1:4
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)β€’ Click on a phase to view related trials

Phase 1
4 (66.7%)
Phase 2
2 (33.3%)

DM-CHOC-PEN for Brain Tumors in AYA Subjects

Phase 2
Completed
Conditions
Advanced Cancer
Brain Metastases
Interventions
First Posted Date
2018-09-13
Last Posted Date
2022-11-08
Lead Sponsor
DEKK-TEC, Inc.
Target Recruit Count
20
Registration Number
NCT03668847
Locations
πŸ‡ΊπŸ‡Έ

Tulane University Medical Center, New Orleans, Louisiana, United States

DM-CHOC-PEN Plus Radiation for Brain Tumors

Phase 1
Completed
Conditions
Advanced Cancer
Interventions
First Posted Date
2017-12-13
Last Posted Date
2022-11-04
Lead Sponsor
DEKK-TEC, Inc.
Target Recruit Count
19
Registration Number
NCT03371004
Locations
πŸ‡ΊπŸ‡Έ

Tulane University Medical Center, New Orleans, Louisiana, United States

πŸ‡ΊπŸ‡Έ

Tulane University Medical School, New Orleans, Louisiana, United States

πŸ‡ΊπŸ‡Έ

Detroit Clinical Research Centers, Detroit, Michigan, United States

A Phase I Trial of DM-CHOC-PEN in Adolescent and Young Adult (AYA) Subjects With Advanced Cancers

Conditions
Advanced Cancer
First Posted Date
2016-09-05
Last Posted Date
2020-08-18
Lead Sponsor
DEKK-TEC, Inc.
Registration Number
NCT02889445
Locations
πŸ‡ΊπŸ‡Έ

Detroit Clinical Research Centers, Detroit, Michigan, United States

Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors

Phase 2
Completed
Conditions
Primary Brain Tumors
Metastatic Malignant Neoplasm to Brain
Interventions
Drug: 4-Demethyl-4-cholestryloxycarbonylpenclomedine
First Posted Date
2014-01-16
Last Posted Date
2020-09-16
Lead Sponsor
DEKK-TEC, Inc.
Target Recruit Count
29
Registration Number
NCT02038218
Locations
πŸ‡ΊπŸ‡Έ

Tulane University Medical Center, New Orleans, Louisiana, United States

πŸ‡ΊπŸ‡Έ

Detroit Clinical Research Centers, Lansing, Michigan, United States

πŸ‡ΊπŸ‡Έ

The University of Texas Health Science Center, Houston, Texas, United States

Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer"

Phase 1
Completed
Conditions
Advanced Cancer
Interventions
First Posted Date
2013-11-06
Last Posted Date
2020-08-04
Lead Sponsor
DEKK-TEC, Inc.
Target Recruit Count
23
Registration Number
NCT01976910
Locations
πŸ‡ΊπŸ‡Έ

Tulane University Medical School, New Orleans, Louisiana, United States

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.